PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Oxatomide→

Oxatomide PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
60607-34-3
Molecular formula
C27H30N4O
Molecular weight
426.6 g/mol
Drug class
Second-generation H1 antihistaminemast-cell stabilising and antiallergic agent
Mechanism of action
Antagonises histamine H1 receptors and inhibits mediator release from mast cells and basophils, including histamine, leukotrienes and prostaglandins. It also inhibits selected calcium-dependent degranulation pathways.
Indications / reported uses
  • Symptomatic treatment of allergic rhinitis, chronic urticaria and selected allergic skin disorders in countries where oxatomide is authorised.

Sources: https://pubmed.ncbi.nlm.nih.gov/1690009/ · https://pubmed.ncbi.nlm.nih.gov/10513346/ · https://www.caymanchem.com/pdfs/42288.pdf · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Oxatomide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Oxatomide Permitted Daily Exposure (PDE) report (the Oxatomide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Oxatomide Occupational Exposure Limit (OEL) report (the Oxatomide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.